IminoTech (Carson City, NV) conducted two clinical studies demonstrating the safety and efficacy of its Q-actin ingredient.
According to IminoTech President Shil Kothari, the studies employed widely accepted clinical measurement tools for joint health studies. These consist of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) which measures joint function; the Visual Analogue Scale (VAS) which measures pain reduction; and Lequesne’s Functional Index (LFI) which measures joint function and the ability to perform daily activities.
The first study was a placebo-controlled study published in 2023 in Current Rheumatology Reviews. The randomized study involved 91 subjects with moderate osteoarthritis. Subjects were divided into three groups taking a placebo, 20 mg of Q-actin or 100 mg of Q-actin daily for six months. Following a baseline evaluation, subjects were evaluated at 30-day intervals using WOMAC, VAS and LFI.
According to Kothari, both Q-actin groups significantly outperformed the placebo group with the 100 mg dose showing the best results across all measures.
“The group taking 20 mg of Q-actin daily showed a significant improvement in joint pain, function and mobility, with around 32 to 40 percent improvement across all measures,” Kothari said. “The group taking the higher dose of 100 mg of Q-actin daily had even greater improvements, with around 40 to 50 percent better joint health, pain reduction and function.”
The second study was a clinical comparison study published in Clinical Interventions in Aging. The randomized, double-blind study demonstrated Q-actin was significantly more effective than glucosamine-chondroitin in relieving knee discomfort and increasing mobility.
The three-country study evaluated 122 me and women aged 40 to 75 with moderate joint health issues related to age. Participants were divided into two groups, consuming 1,350 mg of glucosamine-chondroitin or 10 mg of Q-actin twice daily for six months.
Individuals were evaluated at 30, 60, 90, 120 and 180 days using WOMAC, VAS and LFI. The Q-actin subjects reported significant joint health improvements at every evaluation period, compared with glucosamine-chondroitin, Kothari explained.
According to Kothari, preclinical research also provides insights into the mechanisms of Q-actin’s joint health benefits. Q-actin helps reduce inflammation by targeting different pathways that would otherwise cause joint or tissue damage such as reducing TNF-α, inhibiting enzymes such as α-L-iduronidase and sialidases, and reducing hyaluronic acid.
“In addition, IminoTech also conducted comprehensive safety and toxicology studies that show Q-actin has a strong safety profile” Kothari said. “These included a 90-day study in which rodents were given a single large dose (2,000 mg per kg of body weight) followed by repeated smaller doses (1,000 mg per kg of body weight per day). Q-actin was well-tolerated with no signs of toxicity, no changes in weight, food consumption or any noticeable health issues.”
For more information, visit www.iminotech.com.
